Subjective memory impairment in glioma patients with curative radiotherapy.
Hippocampus
MRI
Neurocognitive evaluation
Radiotherapy
Subjective memory impairment
Journal
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
21
01
2022
revised:
04
04
2022
accepted:
10
04
2022
pubmed:
22
4
2022
medline:
9
6
2022
entrez:
21
4
2022
Statut:
ppublish
Résumé
Radiotherapy in patients with primary brain tumors may affect hippocampal structure and cause dyscognitive side-effects. Using structural MRI and comprehensive neurocognitive evaluation, we investigated associations between hippocampal structure and memory deficits in 15 patients with WHO grade 3 and grade 4 gliomas receiving standard radio(chemo)therapy. We did not find changes in hippocampal thickness or cognitive abilities three months after completing radiotherapy. However, subjective memory impairment was associated with symptoms of depression, but not with objective memory performance, cortical thickness of the hippocampus or radiation dose. Irrespective of whether there is a bidirectional relationship between affective changes and subjective cognitive dysfunction in these patients, depressive symptoms remain a target for intervention to improve their quality of life. The results of our pilot study highlight that future assessment of side effects of radiotherapy concerning memory should include assessments of depressive symptoms.
Sections du résumé
BACKGROUND
Radiotherapy in patients with primary brain tumors may affect hippocampal structure and cause dyscognitive side-effects.
PATIENTS AND METHODS
Using structural MRI and comprehensive neurocognitive evaluation, we investigated associations between hippocampal structure and memory deficits in 15 patients with WHO grade 3 and grade 4 gliomas receiving standard radio(chemo)therapy.
RESULTS
We did not find changes in hippocampal thickness or cognitive abilities three months after completing radiotherapy. However, subjective memory impairment was associated with symptoms of depression, but not with objective memory performance, cortical thickness of the hippocampus or radiation dose.
CONCLUSIONS
Irrespective of whether there is a bidirectional relationship between affective changes and subjective cognitive dysfunction in these patients, depressive symptoms remain a target for intervention to improve their quality of life. The results of our pilot study highlight that future assessment of side effects of radiotherapy concerning memory should include assessments of depressive symptoms.
Identifiants
pubmed: 35447285
pii: S0167-8140(22)00192-X
doi: 10.1016/j.radonc.2022.04.010
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
101-106Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of Interest Declaration Markus Donix, Annekatrin Seidlitz, Maria Buthut, Steffen Löck, Gisa Meissner, Claudia Matthes, Esther G.C. Troost, Felix Raschke, Michael Baumann and Mechthild Krause confirm that there is no conflict of interest for this paper. Markus Donix received research support from the Roland Ernst Stiftung and Doktor Robert Pfleger Stiftung. Dr. Krause received funding for her research projects by IBA (2016), Merck KGaA (2014–2018 for preclinical study; 2018–2020 for clinical study), Medipan GmbH (2014–2018) in the past 5 years. She is involved in an ongoing publicly funded (German Federal Ministry of Education and Research) project with the companies Medipan, Attomol GmbH, GA Generic Assays GmbH, Gesellschaft für medizinische und wissenschaftliche genetische Analysen, Lipotype GmbH and PolyAn GmbH (2019–2021). For the present study, Dr. Krause confirms that none of the above mentioned funding sources were involved. Michael Baumann, CEO and Scientific Chair of the German Cancer Research Center (DKFZ, Heidelberg) is responsible for collaborations with a large number of companies and institutions worldwide. In this capacity, he has signed contracts for research funding and/or collaborations, including commercial transfers, with industry and academia on behalf of his institute(s) and staff. He is a member of several supervisory boards, advisory boards and boards of trustees. Michael Baumann confirms that there is no conflict of interest for this paper. Dr. Troost has been involved in an ongoing publicly funded (German Federal Ministry of Education and Research) project with the companies Medipan, Attomol GmbH, GA Generic Assays GmbH, Gesellschaft für medizinische und wissenschaftliche genetische Analysen, Lipotype GmbH and PolyAn GmbH (2019–2021) in the past 5 years. None of this is related to this publication.